Halozyme Therapeutics Inc (HALO)

Operating return on assets (Operating ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	337,574	311,048	306,061	245,663	267,531	249,556	241,850	300,837	275,902	296,992	261,705	198,213	144,255	34,569	-30,267	-73,799	-67,610	-35,619	-36,556	-42,652
Total assets	US$ in thousands	1,733,270	1,892,660	1,810,440	1,699,450	1,841,510	1,864,540	1,781,390	1,162,250	1,104,430	1,185,420	1,025,860	966,582	579,924	524,029	526,997	492,353	565,874	370,356	417,830	429,109
Operating ROA		19.48%	16.43%	16.91%	14.46%	14.53%	13.38%	13.58%	25.88%	24.98%	25.05%	25.51%	20.51%	24.87%	6.60%	-5.74%	-14.99%	-11.95%	-9.62%	-8.75%	-9.94%

December 31, 2023 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $337,574K ÷ $1,733,270K
= 19.48%

To analyze Halozyme Therapeutics Inc.'s operating return on assets (operating ROA) based on the provided data, we can see fluctuations in the metric over the past eight quarters. Operating ROA indicates the company's efficiency in generating operating income relative to its total assets.

- In Q1 2022, the operating ROA was at a high of 25.88%, reflecting strong operational performance and efficient asset utilization.
- Throughout Q2 and Q3 2022, the operating ROA remained relatively stable in the range of 13.58% to 13.38%.
- In Q4 2022, there was a notable increase to 14.53%, which continued into Q1 2023 at 14.46%. These figures suggest a slight improvement in operational efficiency.
- A significant rise in operating ROA is observed in Q2 2023 to 16.91%, indicating a more robust performance compared to the previous quarters.
- This trend continued into Q3 2023, with a further increase to 16.43%, demonstrating sustained operational effectiveness.
- Q4 2023 witnessed the highest operating ROA during the analyzed period at 19.48%, implying continued improvements in operational income generation relative to assets.

In conclusion, the fluctuating but generally increasing trend in operating ROA for Halozyme Therapeutics Inc. over the past eight quarters suggests improving operational performance and efficiency in utilizing assets to generate operating income.